Lipella Pharmaceuticals Inc.
LIPOOTCHealthcare● Active
$0.10
$-0.01(-4.76%)
Market Cap$462084
P/E Ratio—
52W High$3.17
52W Low$0.02
Lipella Pharmaceuticals Inc. (LIPO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LIPO · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 14, 2025EPS Actual
-$0.28
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 14, 2025
After Market Close
✓ 1-Quarter EPS Beat Streak
LIPO reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$1.28 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | Jun 3, 2026 | — | — | — | — | — | — |
| — Q4 FY2025 | Nov 14, 2025 | — | -$0.28 | — | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$0.31 | — | $0.09B | — | — |
| — Q2 FY2025 | May 14, 2025 | — | -$0.64 | — | $0.13B | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$2.43 | -$1.19 | +51.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.96 | -$1.29 | -34.4% | $0.00B | $0.00B | +0.5% |
| — Q3 FY2024 | Aug 13, 2024 | -$0.96 | -$0.96 | +0.0% | $0.00B | $0.00B | +0.0% |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$1.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 3, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 14, 2025
EPS Actual
-$0.28
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.31
EPS Est.
—
EPS Surpr.
—
Revenue
$0.09B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.64
EPS Est.
—
EPS Surpr.
—
Revenue
$0.13B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$1.19
EPS Est.
-$2.43
EPS Surpr.
+51.0%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$1.29
EPS Est.
-$0.96
EPS Surpr.
-34.4%
Revenue
$0.00B
Q3 FY2024
Aug 13, 2024
EPS Actual
-$0.96
EPS Est.
-$0.96
EPS Surpr.
+0.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-2.43 | $-2.43 | $-2.43 | 1 |
| Q3 FY2026 | $-10.33 | $-10.33 | $-10.33 | 1 |
| Q2 FY2026 | $-0.96 | $-0.96 | $-0.96 | 1 |
| Q1 FY2026 | $-1.28 | $-1.28 | $-1.28 | 1 |
| Q1 FY2025 | $-10.33 | $-10.33 | $-10.33 | 1 |
| Q4 FY2024 | $-0.96 | $-0.96 | $-0.96 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 14, 2025 | — | $0.53 | $0.54 | +1.89% |
| — Q3 FY2025 | Aug 14, 2025 | — | $0.63 | $0.63 | -0.32% |
| — Q2 FY2025 | May 14, 2025 | — | $2.40 | $2.39 | -0.42% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +51.0% | $2.60 | $2.72 | +4.62% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -34.4% | $2.64 | $2.52 | -4.55% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +0.0% | $3.73 | $3.61 | -3.22% |
| ▲ Q2 FY2024 | May 9, 2024 | +0.0% | $5.91 | $6.00 | +1.52% |
| — Q1 FY2024 | Feb 27, 2024 | — | $8.08 | $8.36 | +3.47% |
Q4 FY2025+1.89%
Report Date
Nov 14, 2025
EPS Beat/Miss
—
Price Before
$0.53
Price After
$0.54
Q3 FY2025-0.32%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$0.63
Price After
$0.63
Q2 FY2025-0.42%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$2.40
Price After
$2.39
Q1 FY2025+4.62%
Report Date
Mar 27, 2025
EPS Beat/Miss
+51.0%
Price Before
$2.60
Price After
$2.72
Q4 FY2024-4.55%
Report Date
Nov 14, 2024
EPS Beat/Miss
-34.4%
Price Before
$2.64
Price After
$2.52
Q3 FY2024-3.22%
Report Date
Aug 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$3.73
Price After
$3.61
Q2 FY2024+1.52%
Report Date
May 9, 2024
EPS Beat/Miss
+0.0%
Price Before
$5.91
Price After
$6.00
Q1 FY2024+3.47%
Report Date
Feb 27, 2024
EPS Beat/Miss
—
Price Before
$8.08
Price After
$8.36
Avg Beat Reaction+0.97%
Avg Miss Reaction-4.55%
Beat Rate3 / 8 quarters
Largest Move+4.62% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LIPO ends December
Lipella Pharmaceuticals Inc. (LIPO) most recently reported earnings on November 14, 2025 for Q4 FY2025, posting EPS of $-0.28 (in line with the analyst consensus of —). The next LIPO earnings date is expected around September 1, 2026.
Each quarter, investors track LIPO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LIPO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LIPO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LIPO earnings · 4 questionsLipella Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. LIPO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LIPO historically reports after market close (AMC).
LIPO earnings datewhen is LIPO earningsLIPO next earnings datewhen does LIPO report earningsLIPO earnings calendar
▸ Source: FMP · Lipella Pharmaceuticals Inc. SEC filings · US GAAP · Lipella Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026